In this issue:
Long-term HD14 follow-up confirms superiority of 2+2 strategy for tumour control
PET-guided omission of radiotherapy in early-stage unfavourable HL
Promising early response to first-line anti–PD-1 treatment with nivolumab
Combined HDAC and mTOR inhibition in relapsed/refractory disease
Chemotherapy after anti-PD-1 failure for relapsed/refractory disease
Front-line BEACOPP elicits favourable outcomes versus ABVD in advanced HL
CRT elicits survival benefits in older patients with early-stage NLPHL
Novel salvage options following failure of front-line therapy may improve outcomes
Interim PET/CT is prognostic for PFS and OS in elderly patients
The role of PET in first-line treatment of HL
Please login below to download this issue (PDF)